SOURCE: Alpharma Inc.

October 23, 2007 09:43 ET

Alpharma Appoints John J. Howarth as Vice President, Investor Relations

BRIDGEWATER, NJ--(Marketwire - October 23, 2007) - Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, today announced the appointment of John J. Howarth to Vice President, Investor Relations. Mr. Howarth will succeed Kathleen Makrakis, who will continue with the Company until early next year in a transition capacity.

"We are delighted to bring someone of Jack's caliber and expertise to Alpharma," commented Jeff Campbell, Executive Vice President and Chief Financial Officer. "Jack's extensive background in both the healthcare industry and investor relations will be invaluable as Alpharma continues to focus on the creation of shareholder value through the execution of its growth strategy. I also want to thank Kathy for her significant contributions over the past several years."

Jack Howarth comes to Alpharma with significant experience in finance, investor relations and corporate affairs. He has over 20 years of leadership experience in the healthcare industry, including executive positions at specialty pharmaceutical companies, as well as large global pharmaceutical companies. Most recently, he was Vice President of Public Affairs and Investor Relations at MedPointe Pharmaceuticals; prior to their recent merger with Meda AB. Previously he served as Vice President Investor Relations and Corporate Affairs at Kos Pharmaceuticals. Mr. Howarth's career also includes 17 years at Warner-Lambert. Jack received his BS degree in accounting from Boston College and an MBA in finance from Seton Hall University.

Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded pharmaceutical franchise in the U.S. pain market with its KADIAN® (morphine sulfate extended-release) Capsules, and an innovative pharmaceutical product pipeline that consists of several novel approaches to treat pain, including the Flector® Patch (diclofenac epolamine topical patch), which is expected to launch in early 2008. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.

Alpharma Inc.
440 Route 22 East
Bridgewater, NJ  08807

Contact Information